$ALZN News

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

Alzamend Neuro Announces Pharmacodynamic Findings From Brain Magnetic Resonance Spectroscopy Analysis Conducted In Healthy Human Subjects In Trial Conducted At Massachusetts General Hospital

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Alzamend Announces Topline Data From First Phase II "Lithium In Brain" Clinical Trial, Demonstrating AL001 Meets Bioequivalence Standards, And Showing Numerically Superior Lithium Delivery To Brain Compared To Standard Lithium Carbonate

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro Starts Phase II Clinical Study Of AL001 In Participants With Bipolar Disorder Type 1; Topline Data Anticipated By March End

Alzamend Neuro Enters ATM Sales Agreement To Sell Up To $3.0M In Common Stock

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $28

Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

EXCLUSIVE: Alzamend Neuro Tells Benzinga 'Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects'

EXCLUSIVE: Alzamend Neuro Tells Benzinga 'Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects'

EXCLUSIVE: Alzamend Neuro Tells Benzinga 'Topline data expected in first quarter of 2026'

EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Announces Completion Of Clinical Portion Of Phase II Clinical Trial Of AL001 'Lithium In Brain' Study Conducted At Massachusetts General Hospital

Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42

Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate